Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
The Evidence Forum

The fall issue of The Evidence Forum is out

Read content related to the relevant issues facing companies along the path to approval and access

Read Now
White Paper

Pragmatic Randomized Trials: Considerations for Design and Implementation

Learn how pragmatic randomized trials can collect RWE to meet regulator and payer needs

Read Now
Latest News

Evidera and CSS collaborate to develop joint real-world and patient-centered research capabilities in Japan

Learn More
Latest News

Recent Study Collaboration with ARM and NAMCP

Roadmap for Navigating Cell and Gene Therapy Value Demonstration and Reimbursement in U.S. Managed Care

Learn More
White Paper

The Role of Integrated Scientific Advice for the Early Determination of RWE Requirements in HTA and Payer Assessments

Learn how early dialogue through ISA can be used as a key tool in RWE generation planning

Read Now

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Any

From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs

  • Medical Decision Making
  • November 2019
Oncology

Treatment Patterns and Overall Survival in Metastatic Non-Small-Cell Lung Cancer in a Real-World, US Setting

  • Future Oncology
  • November 2019
Oncology

Automated Extraction of Treatment Patterns from Social Media Posts: An Exploratory Analysis in Renal Cell Carcinoma

  • Future Oncology
  • November 2019
Read More About Our Publications
What We Do

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Market Access

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.
Kevin Marsh

In Our Own Words

Regulators and payers are increasingly using data on patient preferences, and we support our clients in applying these methods to inform decision making across a product’s entire lifecycle.

CUP Case Study
Case Study

Robust Modeling Helped Convince NICE to Reverse Their Decision

Learn how Evidera’s experts helped to improve access to a mCRPC treatment in a country with traditionally conservative reimbursement for these therapies.

Read More
Case Study

Compassionate Use Program: Rapid Drug Delivery to Patients in Need

Learn how Evidera, as part of PPD, created a global program across 38 countries to provide treatment within 24-48 hours to 3,100 patients.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More